Thiotepa for Advanced Breast Cancer
Author Information
Author(s): A. R. Lyons, G. A. Edelstyn
Primary Institution: Northern Ireland Radiotherapy Centre
Hypothesis
Can thiotepa effectively treat advanced breast cancer?
Conclusion
Thiotepa treatment resulted in a low remission rate and significant risks, making it less favorable compared to other treatments.
Supporting Evidence
- Only 32% of patients had an objective remission.
- The mean duration of response was 8 months.
- Patients with bony metastases had a better chance of response.
- Mortality rate from treatment was 11%.
- High doses of thiotepa showed better response rates.
Takeaway
Thiotepa is a medicine used for breast cancer, but it doesn't work very well and can be dangerous.
Methodology
Patients with advanced breast cancer were treated with thiotepa and testosterone, and their responses were monitored.
Potential Biases
Potential bias due to previous hormone treatments affecting outcomes.
Limitations
The study could not reproduce previous high remission rates and had a significant mortality rate.
Participant Demographics
Patients with progressive metastasizing breast cancer, most having prior hormone therapy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website